Buddy Lee—Olympian, Marine, and longtime jump-rope coach—shares how a neighbor’s mentorship turned a “playground toy” into his competitive edge and lifelong mission. He outlines a three-phase progression (Base → Conditioning → Sports Training) built on fundamentals: proper rope fit, upright posture, relaxed grip, and the “four Bs” (Balance, Breathe, Bend, Bounce). Mastery starts with the basic bounce and running step (aiming for 140 clean reps before progressing), then layers foot patterns and intensity safely. The aim isn’t tricks—it’s transferable movement quality, coordination, and durability.
Lee argues that properly coached jump-rope training is low-impact, time-efficient, and evidence-informed for metabolic conditioning, brain health, and bone density—especially valuable for older adults. He cautions against chasing double- or triple-unders without foundations, frames fitness as a community duty, and highlights plans to expand teaching resources. His message is simple and invitational: disciplined practice, done well for 5–10 minutes a day, can restore resilience, inspire confidence, and knit communities back together through movement.
This BSI Medical Society Webinar was streamed on October 15, 2025.
A 10-minute summary of the webinar is available here free, for anyone, while the full video is available for Medical Society Members and MetFix affiliates in their dashboard.
With over 15 years of experience in the health and wellness industry, Karen has developed a strong expertise in health promotion, behavior change, and wellness.
Her mission is to curate vibrant health experiences that inspire, educate, and empower people to live their best lives.
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
